中国当代儿科杂志2026，Vol.28Issue(6)：729-735,7.DOI:10.7499/j.issn.1008-8830.2509114
利妥昔单抗在儿童难治性肾病综合征中的疗效及安全性分析
Efficacy and safety of rituximab in children with refractory nephrotic syndrome
摘要
Abstract
Objective To evaluate the efficacy and safety of rituximab(RTX)in children with frequently relapsing nephrotic syndrome(FRNS)or steroid-dependent nephrotic syndrome(SDNS)after treatment with prednisone combined with standard doses of mycophenolate mofetil and a calcineurin inhibitor.Methods A retrospective analysis was conducted on clinical data from pediatric patients admitted to the Department of Pediatric Nephrology,Peking University First Hospital from January 1,2014 to December 31,2023.These patients had received prednisone plus standard doses of mycophenolate mofetil and a calcineurin inhibitor but still presented with FRNS or SDNS.Outcomes included remission rate,relapse rate,reduction or discontinuation of steroids and oral immunosuppressants after RTX treatment,and adverse events following RTX.Results Eighteen patients were enrolled,receiving 63 courses of RTX treatment.None presented with FRNS or SDNS after RTX treatment.Among them,11 patients experienced no relapse from the first RTX dose to the last follow-up.After RTX administration,the duration of use of all immunosuppressants and the relapse frequency were significantly reduced(P<0.05).Most RTX-related adverse events were mild.Conclusions RTX demonstrates good efficacy and safety in children with FRNS or SDNS after treatment with three immunosuppressive agents.关键词
难治性肾病综合征/利妥昔单抗/三联免疫抑制剂治疗/儿童Key words
Refractory nephrotic syndrome/Rituximab/Triple immunosuppressive therapy/Child引用本文复制引用
白薇,徐可,苏白鸽,刘晓宇,钟旭辉,肖慧捷,姚勇,张宏文,王芳..利妥昔单抗在儿童难治性肾病综合征中的疗效及安全性分析[J].中国当代儿科杂志,2026,28(6):729-735,7.基金项目
中央高水平医院临床科研业务费资助(北京大学第一医院高质量临床研究专项,2023HQ02) （北京大学第一医院高质量临床研究专项,2023HQ02）
中央高水平医院临床科研业务费资助(北京大学第一医院青年临床研究专项,2024YC06). （北京大学第一医院青年临床研究专项,2024YC06）
